More than 76% of small business owners who apply for financing through their system do it from a mobile device. That’s the ...

The next signal is rework. Items that were “done” returning for clarification. Late changes because something was ...

US FDA clears Abbisko Therapeutics' IND application for FGFR2/3 inhibitor, ABSK061 for achondroplasia in children: Shanghai Wednesday, April 1, 2026, 15:00 Hrs [IST] Abbisko Thera ...

ABSK061 is currently being evaluated in a Phase II clinical trial for ACH, and in December 2025, the study dosed its first ...

On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the ...